Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) Return on Equity (2021 - 2025)

Tango Therapeutics (TNGX) has 5 years of Return on Equity data on record, last reported at 0.4% in Q4 2025.

  • For Q4 2025, Return on Equity rose 21.0% year-over-year to 0.4%; the TTM value through Dec 2025 reached 0.4%, up 21.0%, while the annual FY2025 figure was 0.37%, 20.0% up from the prior year.
  • Return on Equity reached 0.4% in Q4 2025 per TNGX's latest filing, up from 0.68% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.15% in Q4 2021 and bottomed at 0.96% in Q2 2025.
  • Average Return on Equity over 5 years is 0.48%, with a median of 0.44% recorded in 2024.
  • Peak YoY movement for Return on Equity: soared 60bps in 2022, then tumbled -51bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.15% in 2021, then plummeted by -170bps to 0.41% in 2022, then rose by 7bps to 0.38% in 2023, then plummeted by -58bps to 0.61% in 2024, then soared by 34bps to 0.4% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.4% in Q4 2025, 0.68% in Q3 2025, and 0.96% in Q2 2025.